Google
Trusted Resources: News & Events
Latest announcements and gatherings
The Upside of Bad Genes
For the last two decades, they’ve had the option of artificially fertilizing embryos and selecting only those that lack the sickle cell trait. Now a new possibility is on the horizon: They may soon be able to edit the offending gene right out of their own sperm, eggs or embryos, erasing it from their bloodline forever.
The technology that will allow this is called Crispr-Cas9. It’s relatively cheap and it permits scientists to change DNA with an ease and precision that until now has been impossible. The promise is that it will transform medicine by vanquishing previously incurable diseases. The method is probably at least a few years away from being applied in clinical settings. Still, some are already worried that, when it comes to improving our own genome, we don’t yet know enough about how genes work to wield this power without unintended consequences.
+myBinderRelated Content
-
First Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
-
Sickle Cell Disease – Hydroxyurea: What You Need to KnowIf you have sickle cell disease, your bo...
-
A Teenager’s Breakthrough Gene Therapy for Sickle Cell DiseaseMeet Helen Obando, a shy 16-year-old who...
-
Siklos (hydroxyurea) now available through ProCare Pharmacy Care’s Siklos At Home programMedunik USA announced today that...
-
The State-of-the-Art Methodology Behind New Sickle Cell Disease GuidelinesSickle cell disease (SCD) is an inherite...
-
NHLBI Stepping Up Efforts to Apprise SCD Patients of Therapies and TrialsWide interest in a CBS 60 Minutes story ...
-
Sancilio Pharmaceuticals Company announces Altemia™ receives orphan drug designation from the European Medicines A...Sancilio Pharmaceuticals Company, Inc. (...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.